Title:
MODIFIED THROMBOPOIETIN WITH REDUCED IMMUNOGENICITY
Document Type and Number:
WIPO Patent Application WO2002068469
Kind Code:
A3
Abstract:
The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human thrombopoietin (TPO) to result in TPO proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
More Like This:
| WO/2012/142659 | SITE-SELECTIVE MODIFICATION OF PROTEINS |
| WO/2023/118532 | LPL1 DERIVED IMMUNE ENHANCING PEPTIDES |
Inventors:
CARR FRANCIS J (GB)
CARTER GRAHAM (GB)
CARTER GRAHAM (GB)
Application Number:
PCT/EP2002/001931
Publication Date:
August 28, 2003
Filing Date:
February 22, 2002
Export Citation:
Assignee:
MERCK PATENT GMBH (DE)
CARR FRANCIS J (GB)
CARTER GRAHAM (GB)
CARR FRANCIS J (GB)
CARTER GRAHAM (GB)
International Classes:
A61K38/04; A61K38/19; C12N15/09; A61K38/22; A61P7/04; C07K7/08; C07K14/52; C12N15/11; C12N15/19; C12P21/02; A61K35/12; (IPC1-7): C12N15/11; C07K14/52; A61K38/04
Domestic Patent References:
| WO1996023888A1 | 1996-08-08 |
Foreign References:
| EP0668352A1 | 1995-08-23 |
Other References:
M DE SERRES ET AL.: "Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB7c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man", STEM CELLS., vol. 17, 1999, ALPHAMED PRESS, DAYTON, OH., US, pages 203 - 209, XP002230261, ISSN: 1066-5099
Download PDF: